LC-MS/MS determination of a farnesyl transferase inhibitor in human plasma and urine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 30, Issue 4, 2002, Pages 1157-1171

  DePuy, M E ^a   Musson, D G ^a   Yu, S ^a   Fisher, A L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Farnesyl transferase inhibitor; FTI; HPLC MS MS; Liquid chromatographic tandem mass spectrometric assay

Indexed keywords

4 [1 (4 CYANOBENZYL) 5 IMIDAZOLYLMETHYL] 1 (3 CHLOROPHENYL)PIPERAZINONE; ACETONITRILE; METHANOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG; WATER;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSTRUMENTATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MONITORING; NEBULIZER; PRIORITY JOURNAL; QUALITY CONTROL; SOLID PHASE EXTRACTION; SPECTROMETER; STANDARD; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION PROCESS;

ALKYL AND ARYL TRANSFERASES; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; MASS SPECTROMETRY;

EID: 0037038385     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(02)00451-X     Document Type: Article

References (6)

1. Buser C.A., Dinsmore C.J., Fernandes C., Greenberg I., Hamilton K., Mosser S.D., Walsh E.S., Williams T.M., Koblan K.S. HPLC/MS characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778123. Anal. Biochem. 290:2001;126-137.
2. Vilella D., Sanchez M., Platas G., Salazar O., Genilloud O., Royo I., Cascales C., Martin I., Diez T., Silverman K.C., Lingham R.B., Singh S.B., Jayasuriya H., Pelaez F. Inhibitors of farnesylation of Ras from a microbial natural products screening program. J. Ind. Microb. Biotechnol. 25:(6):2000;315-327.
3. Buser C., Tohru T., Sepp-Lorenzino L. Expert Opin. Invest. Drugs. 10:(6):2001;1173-1193.
4. Bell I.M. Inhibitors of protein prenylation. Expert Opin. Therap. Patents. 10:(12):2000;1813-1831.
5. Prendergast G. Farnesyl transferase inhibitors: antineoplastic mechanism and clincial prospects. Curr. Opin. Cell Biol. 12:2000;166-172.
6. Britten C.D., Rowinsky E.K., Soignet S., Patnaik A., Yao S.-L., Deutsch P., Lee Y., Lobell R.B., Mazina K.E., McCreery H., Pezzuli S., Spriggs D. A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clinical Cancer Res. 7:2001;3894-3903.